



May 3, 2023

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

**“Strides and Orbicular enter into a strategic partnership to
jointly develop a range of nasal sprays”**

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary

Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Head Off: 201, Devanwata, Sector 17, Vashi, Navi Mumbai - 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2949

- *Partnership to leverage Orbicular's advanced development capabilities with Strides' USFDA approved manufacturing site for Nasal Sprays at Chestnut Ridge, New York*
- *Strides to launch these products Globally through its commercial arms across the regions*

Bangalore and Hyderabad, India, May 03, 2023 - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR, Strides or Company) and Orbicular Pharmaceutical Technologies Private Limited (Orbicular) today informed that they have entered into a strategic partnership to develop, manufacture and commercialize nasal sprays for the global markets.

Orbicular, a speciality pharmaceutical company focused on research and product development, will use its expertise in drug delivery and formulation to develop nasal sprays for global markets. The Company has deployed a thorough product design approach to ensure the nasal sprays are robust, following "Quality-by-Design" principles. Orbicular has a stellar product development and licensing track record across various Complex Injectables, Topicals, Ophthalmic, Parenteral, Nasal Spray, and Inhalation product assets.

Strides will commercialize these nasal sprays across the markets using its commercial engine in the US, Europe, and several other markets. The products will be manufactured at Company's state-of-the-art Chestnut Ridge, New York facility. The facility has comprehensive capabilities for nasal spray manufacturing in the unit dose and multi-dose format, including for controlled substances. The site has been in continuous operation for four decades with approval from USFDA and Drug Enforcement Administration (DEA) with a strong compliance track record. Strides acquired this facility in October 2021 from Endo Inc.

The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of \$400m.

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at www.strides.com.

About Orbicular

Orbicular Pharmaceutical Technologies Private Limited (Orbicular) is a research-oriented pharmaceutical product development company with proven capabilities across various dosage forms. The Company's business strategy revolves around developing niche generic and specialty pharmaceutical products and licensing them to global partners at late stages. The company's ambitious strategic plan is to execute the defined CI-TOP SPIN (Complex Injectables, Topicals, Ophthalmic, Parenteral, Nasal Sprays, and Inhalations) Strategy for both Regulated and Emerging Markets. The Company intelligently selects products and proactively executes regulatory expectations. For details, please visit <https://orbicular.co.in/>

For further information, please contact:

Strides

Badree Komandur

Executive Director – Finance & Group CFO

+91 80 6784 0747

Ankit Gupta

Vice President- Corporate Strategy and Development

+91 80 6784 0145

Email: ankit.gupta@strides.com

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076

Corporate Communication

Pallavi Panchmatia: +91 80 6784 0193

Email: pallavi.panchmatia@strides.com

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com

Boni Mukherjee: +91 96186 82208

boni@fortunapr.com